Waycross Partners’s Biogen BIIB Stock Holding History

Waycross Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,000	Closed	-$1.22M	–	99
2020 Q4	$1.22M	Buy	+5,000	New	+$1.29M	0.76%	37

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Waycross Partners's BIIB Position: Q3 2023 in Review

Waycross Partners sold out of Biogen (BIIB) in Q3 2023, closing a stake of 6,000 shares — an estimated $1.71M sold.

Waycross Partners first reported a position in BIIB in Q1 2023 and held it in 2 quarters. The position peaked at $1.71M in Q2 2023. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.

Waycross Partners reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
Waycross Partners sold 6,000 Biogen shares in Q3 2023, an estimated $1.71M.
Waycross Partners first reported a position in Biogen in Q1 2023 and held it in 2 quarters.
Waycross Partners's Biogen position peaked at $1.71M in Q2 2023.
965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.

Based on Waycross Partners's 13F filing for Q3 2023, filed 13 Nov 2023.